inhibitors have been shown to improve cardiovascular disease outcomes in highrisk patients, but evidence for the cardioprotective effects of angiotensin II receptor blockers (ARBs) is less extensive. The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) and the parallel Telmisartan Randomized AssessmeNt Study in aCE iNtolerant subjects with cardiovascular Disease (TRANSCEND) -which together form The ONTARGET Trial Programmeare long-term, large-scale, double-blind, multinational outcome studies with the primary objectives of determining if the combination of the ARB telmisartan 80 mg and the ACE inhibitor ramipril 10 mg is more effective than ramipril 10 mg alone, and if telmisartan is at least as effective as ramipril (in the case of ONTARGET), and if telmisartan is superior to placebo (in the case of TRANSCEND), in providing cardiovascular protection for high-risk patients. A pre-defined substudy is being conducted within The ONTARGET Trial Programme to compare the effects of these agents, alone and in combination, on cardiac structure and function. The substudy overcomes criticisms of many previous studies, which have been performed in small numbers of patients using suboptimal methodology, by evaluating changes in left ventricular structure and function using sophisticated technology provided by magnetic resonance imaging (MRI). Some 300 randomized patients within ONTARGET, recruited from selected centres in Australia, Canada, Germany, Hong Kong, New Zealand and Thailand, will have MRI undertaken at baseline and at 2-year follow-up. As this method of assessing left ventricular dysfunction is somewhat timeconsuming, expensive and complex, and in the light of current interest in the role of B-type natriuretic peptide (BNP) as a simple, inexpensive diagnostic and prognostic tool, the substudy will also examine whether changes in BNP during follow-up correlated with changes in left ventricular dysfunction.
Introduction
clinically important, as its presence is a strong predictor of cardiovascular events and death in patients with hypertension, 2, 3 in the general population 4, 5 and in patients with coronary artery disease. 6, 7 There is a close link between hypertension and LV wall thickness, with patients with established hypertension displaying substantial increases in LV wall thickness compared with age-matched normotensive individuals. 8 It is now well established that structural changes in the heart are reversible and the regression of LVH should be a therapeutic goal, as it has been shown to be associated with improved cardiovascular prognosis. 9, 10 Much less certainty surrounds the optimal therapeutic approach to the prevention of LVH and how to optimize its regression. This relates partly to the heterogeneity of therapies evaluated, and partly to methodological limitations of studies including small numbers of patients. 11 However, data are emerging to indicate that therapy aimed at the renin -angiotensin system (RAS) with the use of angiotensinconverting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs) may be more effective than conventional blood pressure (BP) lowering therapies. 12, 13 The ONTARGET Trial Programme Large-scale, randomized, major endpoint studies are the best means of producing results that have a large impact on clinical practice, but they also provide an efficient means of obtaining additional mechanistic and other data on the effects of therapy in a subset of patients within the main study. Moreover, multiple hypotheses can be tested in a pre-specified manner from the outset of the study. This approach has been used in the long-term, 
Substudy rationale
Angiotensin II, the principal effector molecule of the RAS, plays a central role in BP-dependent and BP-independent mechanisms leading to LVH. 14 Acting via the type 1 (AT 1 ) receptor, angiotensin II produces pathological changes and induces expression of various growth factors. 15 Pre-clinical studies provide evidence for the importance of angiotensin II in regulating LVM. 16 The pivotal role of the RAS is reinforced by the findings of meta-analyses that have consistently shown that ACE inhibitors and ARBs, which both target the RAS, are superior in regressing LVH to other classes of C Anderson Cardiac MRI substudy 51A 52A anti-hypertensive agents, such as β-blockers, despite similar anti-hypertensive efficacy. 12, 17 The mode of action of ACE inhibitors differs from ARBs. The former class of antihypertensives prevents the conversion of angiotensin I to angiotensin II and elevates bradykinin levels. Blockade of the RAS may be incomplete, however, due to compensatory stimulation of alternative, ACE-independent local tissue pathways of angiotensin II generation. 18 Nevertheless, the Heart Outcomes Prevention Evaluation (HOPE) study demonstrated that the ACE inhibitor ramipril reduced the risks of cardiovascular death, myocardial infarction and stroke in high-risk patients through effects that were not fully explained by BP reduction. 19 In addition, ramipril has also been shown to be effective in regressing LVH. 20, 21 ARBs allow inhibition of the actions of angiotensin II, irrespective of whether it is produced systemically or by local tissue mechanisms, 22 as well as there being the potential for the available angiotensin II to stimulate other receptors (e.g. AT 2 ) that may result in anti-growth and tissue antiproliferation activity. 14 One may speculate that a combination of an ACE inhibitor and ARB may prove more effective than either agent alone. One small-scale study has shown that a combination of telmisartan and ramipril produced greater regression of LVH than either monotherapy. 23 A similar observation was made in patients with type 2 diabetes and LVH on dialysis therapy when treated with the ARB losartan, the ACE inhibitor enalapril, or a combination of losartan plus captopril. 24 This hypothesis is being tested in The ONTARGET Trial Programme (Fig. 1 ), 14 while TRANSCEND is addressing the issue of the effectiveness of ARBs in patients who are unable to be treated with ACE inhibitors due to unacceptable sideeffects, such as angioedema or persistent cough. 14 Telmisartan was selected as the most appropriate ARB in The ONTARGET Trial Programme due to its pharmacological profile; telmisartan reduces BP reliably over a 24-h period 25 and shows cardioprotective effects, including an ability to produce LVH regression as suggested by relatively small-scale studies using two-and threedimensional echocardiography. 26 
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Substudy objectives
The ONTARGET Cardiac MRI Substudy aims to determine whether the effects of the agents being tested involve direct actions on LVM and volume. Specifically, the substudy will compare the effects of telmisartan and ramipril, in combination and alone, over 2 years of double-blind, randomized treatment on LV structure and function in high-risk patients evaluated using sophisticated imaging technology provided by MRI. 27 Although the substudy will focus on changes in LVM, including LV wall thickness, end-diastolic and end-systolic function, LV volume will also be evaluated. The secondary objectives are to determine whether these structural and functional changes are related to changes in electrocardiograms (ECG) and B-type natriuretic peptide (BNP) levels, and to establish whether such changes are consistent across important patient subgroups. Levels of BNP are known to be elevated in coronary artery disease, 28 and BNP is a powerful marker for prognosis and risk stratification in heart failure. 29 There is also some evidence that BNP is a sensitive marker of symptomless LV dysfunction. 30 This has stimulated the current interest in the role of BNP as a simple, inexpensive diagnostic and prognostic tool for LV dysfunction. 31
Substudy population
Consecutive patients aged ≥ 55 years of age and at high risk of cardiovascular disease by virtue of having a history of coronary artery disease, peripheral artery disease, stroke (or recent transient ischaemic event), or diabetes mellitus with end-organ damage, who entered The ONTARGET Trial Programme at 20 sites in six countries have been invited to participate additionally in the Cardiac MRI Substudy. At baseline, their BP was required to be within the 'normal' range. Patients were excluded if there was evidence of atrial fibrillation, congestive heart failure, significant renal disease or hepatic dysfunction, and a contraindication for MRI (e.g. a pacemaker, metal body parts, claustrophobia). All patients were required to provide additional written informed consent.
Substudy design
Patients for the substudy were selected during the open-label, run-in phase in The ONTARGET Trial Programme, and baseline MRI and 12-lead ECGs were performed before randomization (ideally in week 3 of the 3-week run-in phase). A second MRI is to be performed at 2-year follow-up postrandomization. Blood samples for the estimation of BNP levels have also been obtained at baseline and will be collected again after 2 years.
Study treatment
Patients have been randomized to once-daily treatment with telmisartan 80 mg, ramipril 10 mg, or a combination of telmisartan 80 mg plus ramipril 10 mg (ONTARGET), or telmisartan 80 mg or placebo (TRANSCEND).
Magnetic resonance imaging
Magnetic resonance imaging is superior to echocardiography for the quantification of LVM. 27 Its advantages are that it provides high-quality, three-dimensional images, but requires no geometric assumptions and no restriction on the image planes, and clearly distinguishes between the myocardium and blood. 32 In the substudy, MRI is being performed at centres with established expertise in the technique and an ability to 53A 54A C Anderson Cardiac MRI substudy recruit from a large population base. Two images are obtained using equivalent steady-state free precession image acquisitions (e.g. known as true-FISP cine imaging on Siemens scanners) that take about 15 min to perform. All MRI images are being digitally recorded onto compact disk and sent to a central laboratory (the Auckland Cardiac MRI Research Group), which will perform the analyses using trained technicians blinded to the treatment allocation. LVM (including LV wall thickness), ejection fraction and end-systolic LV volume will be calculated from short-and long-axis slices by guide point fitting. 33 Ejection fraction and stroke volume will then be derived. The central laboratory will also evaluate the ECGs.
Determination of B-type natriuretic peptide
Blood samples (5 ml) are to be collected in EDTA tubes, centrifuged and stored at -70°C at each site before being shipped to a central laboratory for analysis using a standard procedure. 34
Sample size
Size estimates are based on indirect evidence of LVH prevalence using echocardiography data, 8 meta-analysis of anti-hypertensive efficacy 12, 35 and direct evidence from MRI studies. 36 A review of the literature revealed that treatment with a single antihypertensive agent can result in change in LVM of 8 -10%, whereas the use of combination therapy may result in an enhanced reduction in the order of 13 -16% in hypertensive patients. The patient population in The ONTARGET Trial Programme is likely to be more heterogeneous than in other primary cardiac MRI studies, and patients with congestive heart failure have been excluded. As a consequence, the treatment difference between monotherapy and combination therapy may be only about 5%. Previous experience also suggests that the standard deviation of change in LVM should be about 8 -10% in each group.
There are two hypotheses being tested hierarchically, however: (i) the superiority of combination therapy compared with both monotherapies; and (ii) if both null hypotheses are rejected, the non-inferiority of telmisartan versus ramipril. With a clinically appropriate non-inferiority margin of (equivalent) treatment effect of 4.5%, the total sample size is 86 per group for a power of 90%. Assuming 15% of the data are missing, 100 patients per group are required for a power of 90% to detect the treatment effects. Thus, a total of 300 patients are required for the ONTARGET Cardiac MRI Substudy.
Data analysis
Comparability of baseline LVH characteristics in the treatment groups will be evaluated using Student's t-test (or the non-parametric equivalents) for continuous variables. The association of baseline variables to the MRI parameters will be assessed by correlation analysis and regression analysis. Differences in cardiac function and structure between treatment groups will be assessed by analysis of variance procedures (or the non-parametric equivalent). BNP levels and ECGs will be correlated with MRI-derived parameters.
Discussion
The 2-year Cardiac MRI Substudy of The ONTARGET Trial Programme has been designed to overcome the deficiencies of many published LVH studies, which have been insufficiently powered, inadequately designed, poorly controlled, and of too short C Anderson Cardiac MRI substudy a duration. 11 The large sample size and relatively long treatment evaluation period of the substudy should provide reliable and clinically relevant data for a broad and heterogeneous patient group at high risk of cardiovascular events.
Magnetic resonance imaging is widely regarded as the 'gold standard' for evaluating LVM. 37 The technique has been used to compare the effect of telmisartan with that of carvedilol, showing that telmisartan produced superior regression of LVH, despite both agents bringing about similar BP reductions. 38 The ONTARGET Cardiac MRI Substudy aims to provide a better understanding of the effects of targeting the RAS, using an ARB and/or ACE inhibitor, on the myocardium. In addition, evaluation of the neurohormone BNP may provide an insight into its prognostic value by examining the correlation between plasma BNP levels with LV structural and functional changes in a large patient population. If consistency is identified across different patient groups, BNP may prove a convenient and inexpensive diagnostic and prognostic tool.
